filgrastim
UkraineDrugs containing this active substance
-
The drug is used to reduce the duration and frequency of neutropenia (a decrease in neutrophil levels) in patients undergoing intensive chemotherapy. It is also prescribed for the mobilization of peripheral blood progenitor cells, for the treatment of persistent neutropenia in patients with HIV infection, and for long-term therapy in severe chronic neutropenia.
Form: solution for injection or infusion
Active substance Dosage filgrastim 48 million IU (480 mcg)/0.5 mL ATC: L03AA02
Manufacturer: Selvita Services Sp. z o.o. (quality control: chemical/physical and biological parameters)
-
The drug is used to reduce the duration and frequency of neutropenia (a decrease in white blood cell levels) in patients undergoing intensive chemotherapy. It is also prescribed for the mobilization of hematopoietic progenitor cells, for the treatment of severe chronic neutropenia (congenital, cyclic, or idiopathic), and to support neutrophil levels in patients with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 30 million IU 300 mcg 05 mL ATC: L03AA02
Manufacturer: Selvita Services Sp. z o.o. (quality control: chemical/physical and biological parameters)
-
The drug is used to reduce the duration and frequency of neutropenia (a decrease in white blood cell levels) in patients undergoing chemotherapy or bone marrow transplantation. It is also used for the mobilization of hematopoietic stem cells and in the treatment of children and adults with severe chronic neutropenia to reduce infectious complications.
Form: solution for injection
Active substance Dosage filgrastim 0.3 mg/ml or 0.48 mg/1.6 ml ATC: L03AA02
Manufacturer: FZ "STADA" LLC
-
The drug is prescribed to shorten the duration of neutropenia and reduce the frequency of febrile neutropenia in patients undergoing chemotherapy. It is also used for stem cell mobilization, in the treatment of severe chronic neutropenia, and to maintain normal neutrophil counts in patients with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 300 mcg (30 million IU)/0.5 mL ATC: L03AA02
-
The drug is prescribed to shorten the duration of neutropenia and reduce the frequency of febrile neutropenia in patients undergoing chemotherapy. It is also used for stem cell mobilization, in the treatment of severe chronic neutropenia (congenital, cyclic, or idiopathic), and to reduce the risk of bacterial infections in patients with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 480 mcg/0.8 mL ATC: L03AA02
-
The drug is used to reduce the duration and frequency of neutropenia (a decrease in neutrophil levels) in patients undergoing intensive chemotherapy. It is also prescribed for the mobilization of hematopoietic progenitor cells, for the treatment of severe chronic neutropenia (congenital, cyclic, or idiopathic), and to support neutrophil levels in patients with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 12 million IU (120 mcg)/0.2 mL ATC: L03AA02
-
The drug is used to reduce the duration and frequency of neutropenia (a decrease in neutrophil levels) in patients undergoing intensive chemotherapy. It is also prescribed for the mobilization of hematopoietic progenitor cells, for the treatment of severe chronic neutropenia (congenital, cyclic, or idiopathic), and to support neutrophil levels in patients with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 30 million IU 300 mcg 05 mL ATC: L03AA02
-
The drug is used to reduce the duration and frequency of neutropenia (a decrease in neutrophil levels) in patients undergoing intensive chemotherapy. It is also used for the mobilization of hematopoietic progenitor cells, for the treatment of severe chronic neutropenia in children and adults, and to support neutrophil levels in patients with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 48 million IU (480 mcg)/0.5 mL ATC: L03AA02
-
The drug is used to shorten the duration of neutropenia (a decrease in neutrophil levels) in patients undergoing chemotherapy. It is also prescribed for stem cell mobilization, for the treatment of severe chronic neutropenia (congenital, cyclic, or idiopathic), and to support neutrophil levels in patients with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 30 million IU/0.5 ml ATC: L03AA02
Manufacturer: Teva Pharmaceutical Industries Ltd. (full-cycle manufacturing)
-
The drug is used to shorten the duration of neutropenia (a decrease in neutrophil levels) in patients undergoing chemotherapy, as well as for stem cell mobilization. It is also prescribed to children and adults with severe chronic neutropenia and to patients with HIV infection to maintain normal neutrophil levels.
Form: solution for injection or infusion
Active substance Dosage filgrastim 48 million IU/0.8 ml ATC: L03AA02
Manufacturer: Teva Pharmaceutical Industries Ltd. (full-cycle manufacturing)
-
Zarxio is used to reduce the duration and severity of neutropenia (a decrease in neutrophil levels) in patients undergoing chemotherapy or bone marrow transplantation. It is also used for the mobilization of hematopoietic stem cells, in the treatment of certain types of congenital neutropenia, and for persistent neutropenia associated with HIV infection.
Form: solution for injection or infusion
Active substance Dosage filgrastim 60 million IU/ml or 30 million IU/0.5 ml ATC: L03AA02
Manufacturer: Sandoz GmbH - Aseptic Medicinal Products Division Schaftenu (Aseptic MPS) (batch release)
-
It is used to reduce the duration and severity of neutropenia (a decrease in white blood cell levels) in patients undergoing chemotherapy or bone marrow transplantation. It is also used for the mobilization of hematopoietic stem cells and the treatment of certain types of chronic neutropenia.
Form: solution for injection or infusion
Active substance Dosage filgrastim 96 million IU/ml or 48 million IU/0.5 ml ATC: L03AA02
Manufacturer: Sandoz GmbH - Aseptic Medicinal Products Division Schaftenu (Aseptic MPS) (batch release)